Equities

CeriBell Inc

CBLL:NSQ

CeriBell Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)25.19
  • Today's Change0.13 / 0.52%
  • Shares traded220.09k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2014
  • Employees--
  • Location
    CeriBell Inc360 N. PASTORIA AVENUESUNNYVALE 94085United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://ceribell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orthopediatrics Corp189.67m-28.44m641.00m247.00--1.73--3.38-1.24-1.248.2615.320.41160.45094.71767,906.90-6.17-5.40-6.78-5.9373.6875.09-15.00-15.923.68-29.230.1638--21.6220.91-1,767.25--28.29--
Iradimed Corp71.31m18.63m674.61m148.0036.468.0834.689.461.461.465.596.590.78511.426.16481,791.5020.5113.1622.4814.5877.1476.5526.1221.467.82143.270.0068.1323.0016.5934.0222.2297.77--
Varex Imaging Corp811.00m-47.70m675.26m2.30k--1.27--0.8326-1.16-1.1619.7713.020.65762.045.05352,608.70-3.83-0.1231-4.54-0.14631.6831.59-5.82-0.17481.971.400.4502---9.220.767-198.96--6.32--
Butterfly Network Inc76.22m-98.51m700.97m225.00--3.85--9.20-0.4708-0.47080.36270.85370.25430.64164.45338,755.60-32.87---38.53--29.60---129.25--2.95--0.00---10.21--20.76------
Orthofix Medical Inc784.25m-119.03m713.84m1.63k--1.36--0.9102-3.14-3.1420.7213.760.88441.176.56479,956.60-13.42-8.88-16.31-10.9668.0572.37-15.18-9.281.11-3.120.2069--62.0610.51-666.60--30.01--
Figs Inc548.65m10.84m798.70m354.0079.821.9848.231.460.0590.0593.082.381.111.3365.261,549,845.002.20--2.64--67.67--1.97--3.28--0.00--7.87--6.85------
Embecta Corp1.12bn69.70m807.83m2.20k11.60--7.460.7221.211.2119.36-13.240.88822.1111.60508,590.905.53--7.91--66.42--6.23--1.612.061.88---0.7703---68.52------
Castle Biosciences Inc311.88m6.08m808.85m610.00144.461.8341.422.590.19990.199911.0715.770.65629.157.15511,275.401.28-9.431.40-10.1781.9080.581.95-28.467.64--0.0228--60.3857.3514.41--117.94--
Avanos Medical Inc681.50m21.70m828.15m3.77k38.510.673412.251.220.46790.338514.7026.760.40311.905.16180,721.301.28-0.65271.45-0.733855.5154.453.18-1.601.469.840.1164---1.580.6357-146.05---18.37--
Cytek Biosciences Inc201.21m-10.16m832.12m645.00--2.17--4.14-0.0782-0.07821.522.970.39821.603.72297,647.90-2.01---2.29--54.92---5.05--5.47--0.0083--17.67---571.58------
Paragon 28 Inc245.00m-63.08m870.95m430.00--6.25--3.55-0.7599-0.75992.951.670.8230.63627.06569,755.80-21.19---25.76--75.22---25.75--1.60-4.200.4424--19.30--28.94------
CeriBell Inc-100.00bn-100.00bn898.43m----------------0.336------------------------2.14--0.6304--74.47--20.72------
Bioventus Inc555.06m-39.48m934.09m1.03k--6.28--1.68-0.6172-0.61728.681.830.70231.954.73572,227.80-6.47-5.52-9.13-7.2767.0068.25-9.22-10.940.98661.130.6725--0.04459.936.91--23.51--
Owens & Minor, Inc.10.66bn-48.79m943.04m13.70k--1.084.260.0885-0.6346-0.6346139.2711.352.097.2615.86778,172.30-0.95611.32-1.492.0720.7216.48-0.45760.56140.45192.030.68310.7983.801.87-284.47--25.91--
Pulse Biosciences Inc0.00-46.13m991.65m56.00--12.53-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
BioLife Solutions Inc118.41m-26.44m1.17bn409.00--3.61--9.89-0.5826-1.012.597.040.29871.695.58289,513.40-6.67-13.76-7.37-15.0446.1536.76-22.33-42.991.78-4.030.0614---11.4348.6552.49--86.35--
Data as of Nov 21 2024. Currency figures normalised to CeriBell Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.